z-logo
open-access-imgOpen Access
Risks and Benefits ofHelicobacter pyloriEradication: Current Status
Author(s) -
Richard H. Hunt,
Carlo A Fallone,
Sander Veldhuyzen van Zanten,
Philip M. Sherman,
Fiona Smaill,
Alan BR Thomson,
the Canadian Helicobacter Study Group
Publication year - 2002
Publication title -
canadian journal of gastroenterology
Language(s) - English
Resource type - Journals
eISSN - 1916-7237
pISSN - 0835-7900
DOI - 10.1155/2002/202961
Subject(s) - medicine , helicobacter pylori , intensive care medicine , peptic ulcer , disease , helicobacter pylori infection , antibiotic resistance , peptic , antibiotics , microbiology and biotechnology , biology
In patients with diseases known to be associated with Helicobacter pylori infection, such as peptic ulcer, treatment of the underlying infection is the standard of care. However, in most major consensus management guidelines, including those published in Canada, widespread testing for H pylori infection is not recommended. This practice is not encouraged because of insufficient evidence of cost-benefit in gastric cancer prevention, the potential for increases in antibiotic resistance and the controversial hypothesis of potential negative effects of eradication in certain clinical entities. For example, there is insufficient evidence to recommend against eradicating H pylori discovered in a patient with symptoms of gastroesophageal reflux disease. The management guidelines designed specifically in Canada should, therefore, continue to be applied, with H pylori diagnosed and treated in appropriately selected patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom